ClinicalTrials.gg
CompletedNCT03949764KeY TreatUpdated Oct 20, 2026Results posted

The Kentucky Viral Hepatitis Treatment Study

A Phase 4 interventional study of Sofosbuvir/velpatasvir (Epclusa®) in Hepatitis C, Opioid-Related Disorders and Injection Drug Use, sponsored by Jennifer Havens. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Jennifer Havens · Phase 4, Interventional, and Treatment

How we know

Updated Oct 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
380
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 725 studies in Hepatitis C with a site in United States — 29 open to participants now, 37 under way, 1 of them phase 3. Hepatitis C · United States.

Enrollment
95th of 594
380 · median 60
Started
2019
with 26 others
Phase 4
85 of 725
2 open now
Registered
644th of 725
by date

Among the 725 studies in Hepatitis C with a site in United States, this one is the 95th largest by enrollment of the 594 interventional ones that give a count, is one of 27 that started in 2019, is one of 85 in phase 4, and was the 644th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

29 of the 725 studies in Hepatitis C with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 725 studies in Hepatitis C with a site in United States, or all of them as a file.
02

Study summary

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.

Read the detailed description

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase access to treatment for the hepatitis C virus (HCV) in a rural Appalachian community in the midst of the opioid/HCV syndemic. This study seeks to examine whether removing barriers associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV (high out-of-pocket costs, insurance restrictions requiring a specialist, abstinence, and significant liver damage) will significantly reduce the burden of HCV in Perry County, Kentucky. The proposed study is made possible by a significant drug donation from Gilead Sciences for sofosbuvir/velpatasvir, a 12-week, once per day, pan-genotypic DAA. KeY Treat proposes a multi-pronged approach to treating HCV using a mid-level provider model. In addition to DAA treatment, participants will be offered access to subsidized medication-assisted treatment, syringe services, and case management. Existing resources in the target community (public health, jail, hospital) will be leveraged, as well as ongoing projects dedicated to increasing access to HCV care in affected communities (ECHO, FOCUS) to answer whether removing the major barriers to HCV treatment affect access, and what barriers remain. All RNA-positive residents of Perry County, Kentucky will be eligible/recruited for study participation (N≈900), and the following specific aims will be addressed: 1) determination of HCV treatment uptake among rural residents with chronic HCV; 2) examination of the predictors of treatment completion among those enrolled in KeY Treat; 3) examination of the characteristics of participants achieving sustained virologic response (SVR, or cure); 4) establishment of long-term re-infection rates among those achieving SVR; 5) examination of 5-year reductions in incidence and prevalence of HCV in the intervention community compared with a control county in rural Kentucky; and 6) evaluate the impact and cost-effectiveness of KeY Treat using mathematical modeling. The proposed research has tremendous potential to impact public health in the rural United States. The majority of counties identified in CDC's recent HCV/HIV hotspot analysis were rural, and there is a real need to improve access to DAAs in order to prevent further HCV transmission, reduce the burden of advanced liver disease, and hepatocellular carcinoma in generations to come. Data from KeY Treat will inform policies around Medicaid/insurance restrictions for DAAs, and will deliver a much needed blueprint for the provision of HCV treatment in resource-deprived rural areas.

03

Conditions studied

  • Hepatitis C
  • Opioid-Related Disorders
  • Injection Drug Use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RNA positive for
  • Perry County residency (verified via ID card showing local address, lease, utility bill, etc.)
  • 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Individuals who are unable to provide consent (to be determined by local study staff in conjunction with our psychiatrist, Dr. Lofwall, a Co-I on the study)
  • Individuals under 18 years of age (study drugs not FDA-approved for those \<18)
  • Pregnant women (unable to participate during duration of pregnancy, but encouraged to return following delivery)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    HCV Positive Study Participants

    Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).

    Drug: Sofosbuvir/velpatasvir (Epclusa®)

  • No intervention
    Control (Pike County)

    After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.

Interventions

  • DrugSofosbuvir/velpatasvir (Epclusa®)

    The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.

06

What researchers measure

Primary outcomes

  1. Participants Who Started HCV Treatment

    Participants who received at least one dose of study medication. This is measured by number of pills left and viral load.

    Time frame: Baseline through Week 12

  2. Participants Who Completed Treatment

    Treatment completion was defined as receiving all prescribed doses of medication. This is measured by pill count and viral load.

    Time frame: Visit 6, 24 weeks post-baseline

  3. Number of Participants With Sustained Virologic Response (SVR)

    Defined as undetectable viral RNA at the 12-week post-completion blood draw (SVR-12).

    Time frame: Visit 7, 50 weeks post-baseline

  4. Number of Participants for Follow-Up Re-Infection Assessment

    Defined as the presence of viral RNA at either the 6- or 12-month follow-up after achieving SVR.

    Time frame: Visit 8, 102 weeks post-baseline

Secondary outcomes

  1. Prevalence of HCV

    Prevalence of HCV in study population, measured by viral load.

    Time frame: Visit 8, 102 weeks post-baseline

  2. Incidence of HCV

    State surveillance data required to calculate HCV incidence were unavailable during the study period; therefore this outcome could not be evaluated.

    Time frame: Visit 8, 102 weeks post-baseline

07

Results

Posted Oct 20, 2026

Participant flow

Medication Protocol
Participant flow — Medication Protocol
MilestoneHCV Positive Study ParticipantsControl (Pike County)
Started3700
Completed2500
Not completed1200
Withdrew: Lost to follow-up1180
Withdrew: Death20
Achieved SVR
Participant flow — Achieved SVR
MilestoneHCV Positive Study ParticipantsControl (Pike County)
Started2500
Completed2330
Not completed170
Withdrew: Death40
Withdrew: Lost to follow-up130
Follow-Up Assessment
Participant flow — Follow-Up Assessment
MilestoneHCV Positive Study ParticipantsControl (Pike County)
Started2330
Completed2150
Not completed180
Withdrew: Death110
Withdrew: Lost to follow-up70

Outcome measures

PrimaryParticipants Who Started HCV Treatment

Participants who received at least one dose of study medication. This is measured by number of pills left and viral load.

Time frame:
Baseline through Week 12
Reported as:
Count of participants · Participants
Participants Who Started HCV Treatment
ParticipantsHCV Positive Study ParticipantsControl (Pike County)
Participants Who Started HCV Treatment3700
PrimaryParticipants Who Completed Treatment

Treatment completion was defined as receiving all prescribed doses of medication. This is measured by pill count and viral load.

Time frame:
Visit 6, 24 weeks post-baseline
Reported as:
Count of participants · Participants
Participants Who Completed Treatment
ParticipantsHCV Positive Study ParticipantsControl (Pike County)
Participants Who Completed Treatment250—
PrimaryNumber of Participants With Sustained Virologic Response (SVR)

Defined as undetectable viral RNA at the 12-week post-completion blood draw (SVR-12).

Time frame:
Visit 7, 50 weeks post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Sustained Virologic Response (SVR)
ParticipantsHCV Positive Study ParticipantsControl (Pike County)
Number of Participants With Sustained Virologic Response (SVR)2330
PrimaryNumber of Participants for Follow-Up Re-Infection Assessment

Defined as the presence of viral RNA at either the 6- or 12-month follow-up after achieving SVR.

Time frame:
Visit 8, 102 weeks post-baseline
Reported as:
Count of participants · Participants
Number of Participants for Follow-Up Re-Infection Assessment
ParticipantsHCV Positive Study ParticipantsControl (Pike County)
Number of Participants for Follow-Up Re-Infection Assessment80
SecondaryPrevalence of HCV

Prevalence of HCV in study population, measured by viral load.

Time frame:
Visit 8, 102 weeks post-baseline
Reported as:
Count of participants · Participants
Prevalence of HCV
ParticipantsHCV Positive Study ParticipantsControl (Pike County)
Prevalence of HCV3700
SecondaryIncidence of HCV

State surveillance data required to calculate HCV incidence were unavailable during the study period; therefore this outcome could not be evaluated.

Time frame:
Visit 8, 102 weeks post-baseline
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

Adverse events

Collected over From initiation of study treatment through the final follow-up visit (approximately 50 weeks post-baseline). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HCV Positive Study Participants41/380 (10.8%)0/380 (0%)0/380 (0%)
Control (Pike County)———

Baseline characteristics

Pike was unable to provide data.

Age, Continuous
Age, Continuous(years)HCV Positive Study ParticipantsControl (Pike County)Total
Mean42.2 ± 0.48—42.2 ± 0.48
Sex: Female, Male
Sex: Female, Male(Participants)HCV Positive Study ParticipantsControl (Pike County)Total
Female157—157
Male223—223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HCV Positive Study ParticipantsControl (Pike County)Total
Hispanic or Latino0—0
Not Hispanic or Latino380—380
Unknown or Not Reported0—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HCV Positive Study ParticipantsControl (Pike County)Total
American Indian or Alaska Native0—0
Asian0—0
Native Hawaiian or Other Pacific Islander0—0
Black or African American13—13
White367—367
More than one race0—0
Unknown or Not Reported0—0
Region of Enrollment
Region of Enrollment(participants)HCV Positive Study ParticipantsControl (Pike County)Total
United States380—380
08

Study locations

1 site
  • ARH Medical Mall
    Hazard, Kentucky 41701, United States
09

References and documents

Publications

  • Havens JR, Schaninger T, Fraser H, Lofwall M, Staton M, Young AM, Hoven A, Walsh SL, Vickerman P. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. BMJ Open. 2021 Jul 5;11(7):e041490. doi: 10.1136/bmjopen-2020-041490. PubMed 34226208 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jun 2025, 69 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 56 non-industry phase 4 interventional studies under Hepatitis C, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 69 months is above that.

Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 16 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2019
First posted
May 14, 2019
StartActual
Sep 23, 2019
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Enrollment
374→380
Oct 20, 2026
Primary outcomes
2 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedNumber of Participants With Sustained Virologic Response (SVR)Time frame: Visit 7, 50 weeks post-baseline
  • ChangedBefore Re-infectionNow Number of Participants for Follow-Up Re-Infection AssessmentTime frame: Visit 8, 102 weeks post-baseline
  • AddedParticipants Who Started HCV TreatmentTime frame: Baseline through Week 12
  • AddedParticipants Who Completed TreatmentTime frame: Visit 6, 24 weeks post-baseline
  • RemovedTreatment UptakeTime frame: Visits 1-5, 1 to 12 weeks post-baseline
  • RemovedTreatment CompletionTime frame: Visit 6, 24 weeks post-baseline
Oct 20, 2026
Documents
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionIncidence of HCV: how it is measured was reworded
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Enrollment 374→380
    Primary outcomes 2 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedNumber of Participants With Sustained Virologic Response (SVR)Time frame: Visit 7, 50 weeks post-baseline
    • ChangedBefore Re-infectionNow Number of Participants for Follow-Up Re-Infection AssessmentTime frame: Visit 8, 102 weeks post-baseline
    • AddedParticipants Who Started HCV TreatmentTime frame: Baseline through Week 12
    • AddedParticipants Who Completed TreatmentTime frame: Visit 6, 24 weeks post-baseline
    • RemovedTreatment UptakeTime frame: Visits 1-5, 1 to 12 weeks post-baseline
    • RemovedTreatment CompletionTime frame: Visit 6, 24 weeks post-baseline
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionIncidence of HCV: how it is measured was reworded
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03949764
Lead sponsor
Jennifer Havens
Responsible party
Jennifer Havens (Professor, University of Kentucky) — Sponsor-investigator
First posted
May 14, 2019
Start date
Sep 23, 2019
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Jennifer Havens, PhD
principal investigator · University of Kentucky Ctr on Drug & Alcohol Rsrch

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion